Basic Information
| LncRNA/CircRNA Name | MIR503HG |
| Synonyms | NA |
| Region | GRCh38_X:134543337-134546632 |
| Ensemble | ENSG00000223749 |
| Refseq | NR_024607 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | triple negative breast cancer |
| ICD-0-3 | C50 |
| Methods | RT-PCR, Western blotting etc. |
| Sample | primary breast cancer tissue samples and 30 corre- sponding adjacent normal mammary tissue samples??wo human triple negative breast cancer cell lines (MDA-MB-231 and TB549) and a human normal breast epithelial cell line (MCF-10A) |
| Expression Pattern | down-regulated |
| Function Description | MIR503HG expression was significantly decreased in triple-negative breast cancer tissues and cell lines. Furthermore, we observed low MIR503HG expression was correlated with late clinical stage, lymph node metastasis and distant metastasis. In the survival analysis, we observed that triple-negative breast cancer patients with low MIR503HG expression had a statistically significant worse prognosis compared with those with high MIR503HG expression, and low MIR503HG expression was a poor independent prognostic factor for overall survival in triple-negative breast cancer patients. The study in vitro suggested MIR503HG inhibits cell migration and invasion via miR-103/OLFM4 axis in triple negative breast cancer. |
| Pubmed ID | 31062436 |
| Year | 2019 |
| Title | LncRNA MIR503HG inhibits cell migration and invasion via miR-103/OLFM4 axis in triple negative breast cancer |
External Links
| Links for MIR503HG | GenBank HGNC NONCODE |
| Links for triple negative breast cancer | OMIM COSMIC |